Spontaneous urinoma debuting as retroperitoneal abscess: report of 2 cases and literature review.

Spontaneous urinoma is a urological entity that can be complicated by a retroperitoneal abscess. Urinoma can be iatrogenic, traumatic, or can be caused by obstructive uropathy. We report two cases of spontaneous urinomas, describing a not previously published cause of urinoma: pyeloureteritis. (I) A 55-year-old Caucasian female started with intense left-sided flank pain for 3 days. CT scan revealed a voluminous retroperitoneal abscess, which extended through the posterior pararenal space and the left lumbar paravertebral musculature. (II) A 48-year-old Caucasian male presented with constitutional symptoms over the previous 2 months and investigations showed a voluminous urinoma and marked pyeloureteritis findings on CT scan. Both patients were managed by endoscopic placement of a double-J stent and drainage of the collection (open and percutaneous approach, respectively). Urinoma was confirmed by fluid biochemical analysis, which demonstrated that fluid creatinine was markedly raised as compared to the serum creatinine. Urinoma in the absence of obstruction or trauma is rare. These two case reports highlight one of the conditions leading to urinoma and the management of retroperitoneal abscess. Pyeloureteritis is a cause of spontaneous urinoma and it should be considered in the lack of another obstructive cause.

Long-term results of the treatment of complex ureteral stenosis with extra-anatomic ureteral bypasses.

INTRODUCTION: Complex ureteral obstruction is a pathology that has always been a challenge for the urologist, especially in patients with high surgical risk or with a short life expectancy. MATERIAL AND METHODS: Between 2002 and 2017, 13 extra-anatomical bypasses were placed. A descriptive retrospective study was carried out. An analysis of the permeability time of the prosthesis was performed using Kaplan-Meyer curves. Demographic and etiological characteristics as well as early and late complications were analysed. RESULTS: Etiologies were benign in 39% (including 3 transplant recipients) and malignant in 69%. Permeability rates were 90.9% at each of 12, 24 and 48 months, respectively, and 75.8% at 60 months. There were no deaths in the early postoperative period, nor intraoperative complications. The most frequent complications were infections. Three of them were associated with bypass extrusion, which needed to be removed. A total of 5 prosthesis had to be removed. 40% of the patients did not present complications. CONCLUSIONS: The extra-anatomical ureteral bypass is an alternative to permanent nephrostomy in the treatment of complex ureteral strictures. Their patency rates after long-term follow-up vary from 90% to 75% at 48 and 60 months, respectively. Their complication rates can be considered acceptable in the patients' clinical contexts.

La integración de la cirugía y el tratamiento quimioterápico en el cáncer de vejiga infiltrante / Comprehensive surgical and chemotherapy treatment for invasive bladder cancer

Introducción: El tratamiento del cáncer vesical de células transicionales con invasión muscular sigue siendo difícil, debido a los múltiples patrones de comportamiento biológico que muestra esta enfermedad. Hay controversia en cuanto a la aplicación de tratamiento sistémico en el carcinoma vesical infiltrante y el momento ideal de la indicación de la quimioterapia perioperatoria. Se presenta una visión general de la terapia sistémica en cáncer vesical infiltrante. Material y métodos: Realizamos una búsqueda informática en PubMed limitando la información a los últimos 5 años y seleccionamos artículos en inglés y en español referentes a “chemotherapy in bladder cancer”. Se seleccionaron estudios aleatorizados, metaanálisis y ensayos clínicos. Resultados: Obtuvimos 241 artículos. Un total de 31 artículos fueron referentes a quimioterapia neoadyuvante y adyuvante en el carcinoma vesical infiltrante. Agrupamos los artículos en tres grupos según su referencia a neoadyuvancia, adyuvancia o neoadyuvancia y adyuvancia de forma conjunta. Dicha información se encuentra reflejada en las tablas anexas al manuscrito. Conclusiones: El abordaje multidisciplinario en el tratamiento del carcinoma vesical infiltrante es indispensable para garantizar un adecuado control oncológico. La evaluación detallada y la selección adecuada del paciente son la herramienta fundamental para determinar el mejor momento para indicar la quimioterapia (AU)

Introduction: Treating patients with invasive transitional cell carcinoma of the bladder remains difficult due to the multiple biological behaviour patterns found in this disease. There is still controversy regarding the use of systemic treatment in invasive bladder carcinoma and the ideal moment for launching perioperative chemotherapy. We present an overview of current trends for systemic treatment of invasive bladder carcinoma. Material and methods: Using MEDLINE, we reviewed relevant English and Spanish language literature published during the last five years, with “chemotherapy in bladder cancer” as key words. We selected randomized trials, meta-analyses and clinical trials. Results: We obtained a total of 241 articles. Thirty-one of them referred to neoadjuvant and adjuvant chemotherapy in invasive bladder cancer. We classified the articles in three different groups neoadjuvant, adjuvant and neoadjuvant plus chemotherapy. All of that information is displayed in the tables within the text. Conclusions: A multidisciplinary approach to the treatment of invasive bladder cancer is essential to guarantee adequate oncological control. A detailed evaluation and proper selection of each patient is fundamental in determining the best moment to start chemotherapy (AU)

Comprehensive surgical and chemotherapy treatment for invasive bladder cancer.

INTRODUCTION: The treatment of transitional cell bladder cancer with muscular invasion remains difficult, due to the numerous patterns of biological behaviour of the disease. There is controversy regarding the application of systemic therapy in invasive bladder carcinoma and the ideal time for the indication of perioperative chemotherapy. This is an overview of systemic therapy in invasive bladder cancer. MATERIALS AND METHODS: Using MEDLINE, we reviewed relevant English and Spanish literature published during the last five years, with "chemotherapy in bladder cancer" as keywords. We selected randomised trials, meta-analyses and clinical trials. RESULTS: We obtained 241 articles, 31 of which referred to neoadjuvant and adjuvant chemotherapy in invasive bladder cancer. We classified the articles into three different groups: neoadjuvant, adjuvant and neoadjuvant plus chemotherapy. This information is shown in the tables within the text. CONCLUSIONS: A multidisciplinary approach to the treatment of invasive bladder cancer is essential to guarantee adequate oncological control. Detailed evaluation and proper selection of each patient is fundamental in determining the best moment to start chemotherapy.